Ensign Peak Advisors Inc Trims Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Ensign Peak Advisors Inc cut its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 12.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,667 shares of the specialty pharmaceutical company’s stock after selling 1,550 shares during the quarter. Ensign Peak Advisors Inc’s holdings in ANI Pharmaceuticals were worth $696,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of ANI Pharmaceuticals by 4,636.4% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after buying an additional 510 shares during the period. National Bank of Canada FI acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at about $79,000. Emerald Advisers LLC increased its position in shares of ANI Pharmaceuticals by 414.8% in the second quarter. Emerald Advisers LLC now owns 1,256 shares of the specialty pharmaceutical company’s stock valued at $82,000 after buying an additional 1,012 shares in the last quarter. Finally, KLP Kapitalforvaltning AS raised its position in ANI Pharmaceuticals by 23.3% during the second quarter. KLP Kapitalforvaltning AS now owns 3,700 shares of the specialty pharmaceutical company’s stock worth $241,000 after acquiring an additional 700 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Buying and Selling

In other news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $87.27, for a total value of $34,908.00. Following the completion of the transaction, the vice president owned 75,274 shares in the company, valued at $6,569,161.98. This trade represents a 0.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Patrick D. Walsh sold 8,643 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $86.88, for a total transaction of $750,903.84. Following the completion of the sale, the director owned 61,405 shares in the company, valued at $5,334,866.40. This represents a 12.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 32,871 shares of company stock valued at $2,963,993 in the last three months. 11.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ANIP shares. Guggenheim raised their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Weiss Ratings reissued a “buy (b-)” rating on shares of ANI Pharmaceuticals in a research report on Monday, November 24th. Truist Financial lifted their price objective on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. HC Wainwright raised their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Finally, JPMorgan Chase & Co. upped their target price on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $99.29.

ANI Pharmaceuticals Trading Up 0.6%

NASDAQ ANIP opened at $84.88 on Monday. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $99.50. The stock has a market capitalization of $1.91 billion, a P/E ratio of -110.23 and a beta of 0.54. The firm has a 50-day moving average price of $89.68 and a 200 day moving average price of $79.22.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.ANI Pharmaceuticals’s revenue was up 53.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.